CRISPR Therapeutics AG(CRSP)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
CRSP | 5.06 B | - | 1041.40% | 0.00% | -$4.72 | -26.10% | 0.45x | 0.00% | $78.48 | $44.12 |
688235.SS | 28.82 B | 86.98x | 29.60% | 10.70% | $2.88 | 14.66% | 0.40x | 0.00% | $319.24 | $205.51 |
IDIA.SW | 1.17 B | - | -26.80% | -158.32% | -$1.38 | - | - | 0.00% | $7.56 | $2.80 |
MLTX | 916.6 M | - | - | 0.00% | -$3.76 | -67.48% | 0.24x | 0.00% | $23.29 | $6.56 |
KURN.SW | 722.1 M | 95.79x | 45.50% | 5.13% | $0.19 | 10.73% | 0.11x | 0.00% | $34.20 | $16.46 |
Peer Valuation & Performance Analysis
Peer group analysis for CRISPR Therapeutics AG (CRSP) compared to its primary competitors (including 688235.SS, IDIA.SW, MLTX) reveals distinct metrics. CRSP trades at a valuation discount relative to its competitors, with a P/E ratio of -11.1x versus the peer average of 44.2x (representing a 125% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, CRSP's revenue growth of 1041.4% exceeds the peer average of 16.1%, highlighting its competitive strength and market share gains. Additionally, it boasts superior profitability with a net margin of 0.0% compared to the peer average of -35.6%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• CRSP ranks #0 in P/E ratio, #1 in revenue growth, and #3 in profit margins
• Average ranking: #1 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-07 | $53.00 | $54.59 | $52.27 | $52.35 | 1,679,200 | -3.06% |
| 2026-10-06 | $60.38 | $60.68 | $53.74 | $54.00 | 2,622,800 | -5.82% |
| 2026-10-05 | $55.21 | $57.46 | $54.01 | $57.34 | 1,701,300 | +3.45% |
| 2026-10-02 | $56.45 | $57.58 | $54.09 | $55.43 | 1,128,300 | -0.02% |
| 2026-10-01 | $55.45 | $56.59 | $54.82 | $55.44 | 1,058,000 | +0.22% |
| 2026-09-30 | $56.55 | $57.11 | $55.28 | $55.32 | 1,165,000 | -1.21% |
| 2026-09-29 | $54.08 | $56.48 | $54.00 | $56.00 | 1,576,100 | +3.53% |
| 2026-09-28 | $53.84 | $55.63 | $52.90 | $54.09 | 1,269,700 | -0.26% |
| 2026-09-25 | $56.14 | $56.39 | $53.92 | $54.23 | 1,007,800 | -2.64% |
| 2026-09-24 | $54.95 | $57.17 | $53.79 | $55.70 | 1,554,900 | -0.11% |
| 2026-09-23 | $59.10 | $59.52 | $54.67 | $55.76 | 2,361,400 | -5.54% |
| 2026-09-22 | $58.73 | $60.72 | $57.64 | $59.03 | 2,080,800 | +1.20% |
| 2026-09-21 | $57.98 | $59.24 | $56.87 | $58.33 | 1,813,500 | +3.13% |
| 2026-09-18 | $58.00 | $59.34 | $55.63 | $56.56 | 3,382,000 | -1.33% |
| 2026-09-17 | $53.90 | $59.21 | $53.12 | $57.33 | 2,997,100 | +9.80% |
Explore More Analysis for CRSP
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.